AW
VRTX icon

Avion Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Avion Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26K Buy
53
+14
+36% +$6.21K ﹤0.01% 345
2026
Q1 		$17K Buy
39
+5
+15% +$2.33K ﹤0.01% 378
2025
Q4 		$15K Buy
34
+12
+55% +$5.17K ﹤0.01% 404
2025
Q3 		$8K Sell
22
-9
-29% -$3.76K ﹤0.01% 555
2025
Q2 		$13K Buy
31
+2
+7% +$922 ﹤0.01% 409
2025
Q1 		$11K Hold
29
– – ﹤0.01% 390
2024
Q4 		$11K Buy
29
+3
+12% +$1.39K ﹤0.01% 389
2024
Q3 		$12K Buy
26
+2
+8% +$961 ﹤0.01% 347
2024
Q2 		$11K Buy
24
+7
+41% +$3.04K ﹤0.01% 325
2024
Q1 		$8K Buy
17
+3
+21% +$1.27K ﹤0.01% 367
2023
Q4 		$6K Sell
14
-9
-39% -$3.33K ﹤0.01% 383
2023
Q3 		$7K Buy
23
+8
+53% +$2.8K ﹤0.01% 321
2023
Q2 		$5K Buy
15
+11
+275% +$3.71K ﹤0.01% 365
2023
Q1 		$1K Buy
+4
New +$1.2K ﹤0.01% 495

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Avion Wealth's VRTX Position: Q2 2026 in Review

Avion Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 36% in Q2 2026, buying an estimated $6.21K and bringing the position to 53 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #345.

Avion Wealth first reported a position in VRTX in Q1 2023 and has held it in 14 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Avion Wealth held 53 shares of Vertex Pharmaceuticals worth $26K as of Q2 2026.
  • Avion Wealth bought 14 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.21K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Avion Wealth's portfolio in Q2 2026, its #345 holding.
  • Avion Wealth first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Avion Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.